Clinical Trials in France / NCT07299500
Recruiting
Observational
Study of a Cohort of Non-HIV Immunocompromised Patients With Toxoplasmosis at the Strasbourg University Hospital
NCT07299500 · tracked via the Priya Life Science France tracker
Condition(s) studied
Cerebral Toxoplasmosis
Study summary
Toxoplasmosis in HIV-positive individuals is well-studied and has a codified management protocol, which is not the case for other immunodeficiencies, except for recent recommendations in the context of hematopoietic stem cell transplantation. A description of this population is necessary to estimate the number of patients affected and to define their specific management (diagnosis, treatment, prevention).
Eligibility
Inclusion Criteria:
* Adult (≥18 years)
* Immunocompromised (i.e., solid organ transplant recipient, hematological malignancy, cancer patient, patient treated with immunosuppressive therapy or therapy affecting the immune system by any mechanism, hematopoietic stem cell transplant recipient, patient with an autoimmune disease or immunodeficiency, whether primary or secondary).
* At least one positive toxoplasmosis PCR test (regardless of tissue)
Exclusion Criteria:
* Subject who has expressed opposition to the reuse of their data for scientific research.
* HIV positive
* Congenital toxoplasmosis
* Isolated ocular toxoplasmosis in immunocompetent individuals
Primary outcome measure(s)
- Overall patient survival rates — Up to 1 year
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Service d'immunologie clinique - Hôpitaux Universitaires de Strasbourg | Strasbourg | France | Recruiting |
More University Hospital, Strasbourg, France trials in France
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07299500 on ClinicalTrials.gov ↗ ← All trials in France